Zevra Therapeutics, Inc.
ZVRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $385,735 | $232,214 | $158,304 | $259,265 |
| - Cash | $33,785 | $43,049 | $65,466 | $112,346 |
| + Debt | $60,296 | $43,765 | $14,123 | $1,609 |
| Enterprise Value | $412,246 | $232,930 | $106,961 | $148,528 |
| Revenue | $23,612 | $27,461 | $10,161 | $28,650 |
| % Growth | -14% | 170.3% | -64.5% | – |
| Gross Profit | $16,195 | $24,516 | $9,939 | $26,591 |
| % Margin | 68.6% | 89.3% | 97.8% | 92.8% |
| EBITDA | -$76,400 | -$43,542 | -$25,526 | -$7,888 |
| % Margin | -323.6% | -158.6% | -251.2% | -27.5% |
| Net Income | -$105,511 | -$46,049 | -$26,772 | -$8,555 |
| % Margin | -446.9% | -167.7% | -263.5% | -29.9% |
| EPS Diluted | -2.28 | -1.3 | -0.78 | -2.11 |
| % Growth | -75.4% | -66.7% | 63% | – |
| Operating Cash Flow | -$69,665 | -$33,535 | -$18,717 | $10,439 |
| Capital Expenditures | $0 | -$296 | -$93 | -$102 |
| Free Cash Flow | -$69,665 | -$33,831 | -$18,810 | $10,337 |